Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
Stephen A. Harrison, Federico Pérez Manghi, William B. Smith, Diana Alpenidze, Diego Aizenberg, Naomi B. Klarenbeek, Chi-Yi Chen, Eli Zuckerman, Éric Ravussin, Phunchai Charatcharoenwitthaya, Pin‐Nan Cheng, Helena Katchman, Samuel Klein, Ziv Ben‐Ari, Anisha E. Mendonza, Yiming Zhang, Miljen Martić, Shenglin Ma, Sheena Kao, Sandra Tanner, Alok S. Pachori, Michael K. Badman, Yanling He, Chinweike Ukomadu, Éric Sicard
Topics & Concepts
PlaceboMedicineInternal medicineClinical endpointGastroenterologyConfidence intervalNonalcoholic steatohepatitisSteatohepatitisMetforminRandomized controlled trialNonalcoholic fatty liver diseaseFatty liverDiseasePathologyAlternative medicineInsulinLiver Disease Diagnosis and TreatmentPancreatitis Pathology and TreatmentPancreatic and Hepatic Oncology Research